2024年5月02日
Life Sciences Reverse Mergers Gain Momentum & Attention
Speakers:
- Brian D. Hirshberg,
- Anna T. Pinedo,
- Polia Nair
For life sciences companies, reverse merger transactions have become increasingly popular. However, merging into a public life sciences company that has experienced a failed clinical program often raises heightened SEC scrutiny and raises legal considerations. During this session, we will discuss:
- Structuring alternatives;
- Recent transactions structured as reverse mergers into public companies;
- SEC comments in connection with recent reverse mergers;
- Documentation, process and timeline;
- New SEC Rule 145a and considerations to avoid shell company status;
- Accounting for reverse acquisitions under US GAAP;
- Accompanying PIPE and other financing transactions; and
- Addressing board and employee matters, anticipating litigation and mitigating liability for the board of the new company.
For additional information, please contact Caitlin Kaplan at ckaplan@mayerbrown.com or +1 212 506 2103.
